GlassScriptPhysician profile
Verna C Guanzon
NPI 1861652331
$27,326.53
in general payments reported to CMS, 2019-2025
52 companies · $3,280 in 2025
The $3,280 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,418 · 2020: $2,879 · 2021: $6,185 · 2022: $4,013 · 2023: $3,820 · 2024: $3,730 · 2025: $3,280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,805.68 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $5,278.97 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $3,860.02 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $2,506.43 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $1,990.93 | 2019-2023 | Xarelto |
| Amgen INC. | $1,836.12 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $1,329.02 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,250.71 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $1,063.15 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Esperion Therapeutics, INC. | $774.02 | 2020-2025 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $609.13 | 2020-2025 | Rexulti, Nuedexta |
| Biohaven Pharmaceuticals, INC. | $563.86 | 2020-2021 | |
| Abbott Laboratories | $502.29 | 2019-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $473.32 | 2019-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $462.48 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $423.29 | 2019-2021 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Verna Guanzon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.